Suda, Takafumi

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 148

Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)

Kono, M., Nakamura, Y., Suda, T., Kato, M., Kaida, Y., Hashimoto, D., Inui, N., Hamada, E., Miyazaki, O., Kurashita, S., et al. (2011) · Clinica Chimica Acta

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisConnective Tissue Growth Factor Research

Cited by 79

Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.

Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 70

Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial

Sakamoto, S., Kataoka, K., Kondoh, Y., Kato, M., Okamoto, M., Mukae, H., Bando, M., Suda, T., Yatera, K., Tanino, Y., et al. (2021) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 67

LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis

Enomoto, Y., Matsushima, S., Shibata, K., Aoshima, Y., Yagi, H., Meguro, S., Kawasaki, H., Kosugi, I., Fujisawa, T., Enomoto, N., et al. (2018) · Clinical Science

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 60

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 59

The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis

Nishimoto, K., Fujisawa, T., Yoshimura, K., Enomoto, Y., Enomoto, N., Nakamura, Y., Inui, N., Sumikawa, H., Johkoh, T., Colby, T. V., et al. (2018) · Respirology

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPleural and Pulmonary Diseases

Cited by 47

HDAC3 is required for XPC recruitment and nucleotide excision repair of DNA damage induced by UV irradiation

Nishimoto, K., Niida, H., Uchida, C., Ohhata, T., Kitagawa, K., Motegi, A., Suda, T., & Kitagawa, M. (2020) · Molecular Cancer Research

DNA Repair MechanismsHistone Deacetylase Inhibitors Research

Cited by 21

Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition

Bando, M., Homma, S., Date, H., Kishi, K., Yamauchi, H., Sakamoto, S., Miyamoto, A., Goto, Y., Nakayama, T., Azuma, A., et al. (2024) · Respiratory Investigation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 12

Liganded T3 receptor β2 inhibits the positive feedback autoregulation of the gene for GATA2, a transcription factor critical for thyrotropin production

Hirahara, N., Nakamura, H. M., Sasaki, S., Matsushita, A., Ohba, K., Kuroda, G., Sakai, Y., Shinkai, S., Haeno, H., Nishio, T., et al. (2020) · PLOS ONE

Thyroid Disorders and TreatmentsEstrogen and related hormone effects

Cited by 9